A Multicenter, Randomized, Double-Blind, Controlled, Phase III Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity in Population Aged 18 Years Old and Above

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trivalent recombinant protein COVID-19 vaccine WestVac Biopharma (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Westvac Biopharma

Most Recent Events

25 Jul 2024 Planned End Date changed from 30 Jul 2025 to 30 Dec 2025.
25 Jul 2024 Planned initiation date changed from 30 Jun 2024 to 30 Dec 2024.
22 Apr 2024 Planned End Date changed from 30 Dec 2024 to 30 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight